Pacific Biosciences of California, Inc. Stock Deutsche Boerse AG

Equities

P09

US69404D1081

Advanced Medical Equipment & Technology

Market Closed - Deutsche Boerse AG 03:50:37 2024-04-19 pm EDT 5-day change 1st Jan Change
1.422 EUR +7.56% Intraday chart for Pacific Biosciences of California, Inc. -52.55% -83.94%
Sales 2024 * 194M 182M Sales 2025 * 294M 276M Capitalization 422M 396M
Net income 2024 * -281M -264M Net income 2025 * -234M -220M EV / Sales 2024 * 4.28 x
Net Debt 2024 * 409M 384M Net Debt 2025 * 493M 463M EV / Sales 2025 * 3.11 x
P/E ratio 2024 *
-1.41 x
P/E ratio 2025 *
-1.74 x
Employees 796
Yield 2024 *
-
Yield 2025 *
-
Free-Float 97.18%
More Fundamentals * Assessed data
Dynamic Chart
Scotiabank Adjusts Pacific Biosciences of California's Price Target to $8 From $15, Maintains Sector Outperform Rating MT
Goldman Sachs Downgrades Pacific Biosciences of California to Neutral From Buy, Adjusts Price Target to $2.50 From $7 MT
TD Cowen Adjusts Price Target on Pacific Biosciences of California to $2.50 From $12, Maintains Buy Rating MT
Sector Update: Health Care Stocks Higher Late Afternoon MT
Sector Update: Health Care MT
Pacific Biosciences of California Q1 Revenue Expected to Be Flat Year Over Year; Guidance Lowered; Shares Sink MT
Pacific Biosciences of California, Inc. Provides Revenue Guidance for the Second Quarter and Full Year 2024 CI
Goldman Sachs Cuts Price Target on Pacific Biosciences of California to $7 From $9, Maintains Buy Rating MT
Estonia National Biobank Selects PacBio to Sequence 10,000 Whole Genomes CI
Transcript : Pacific Biosciences of California, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 10:15 AM
PacBio Announces PureTarget Repeat Expansion Panel, Expanding Its Portfolio of End-To-End Clinical Research Solutions CI
UBS Trims Pacific Biosciences of California Price Target to $12 From $12.50, Maintains Buy Rating MT
Pacific Biosciences of California Q4 Non-GAAP Loss Narrows, Revenue Rises; Shares Drop After Hours MT
Transcript : Pacific Biosciences of California, Inc., Q4 2023 Earnings Call, Feb 15, 2024
Earnings Flash (PACB) PACIFIC BIOSCIENCES OF CALIFORNIA Reports Q4 Revenue $58.4M, vs. Street Est of $58.3M MT
More news
1 day+7.56%
1 week-52.55%
Current month-57.78%
1 month-57.48%
3 months-76.14%
6 months-75.29%
Current year-83.94%
More quotes
1 week
1.18
Extreme 1.1804
3.20
1 month
1.18
Extreme 1.1804
3.64
Current year
1.18
Extreme 1.1804
8.43
1 year
1.18
Extreme 1.1804
13.19
3 years
1.18
Extreme 1.1804
30.11
5 years
1.18
Extreme 1.1804
45.80
10 years
1.18
Extreme 1.1804
45.80
More quotes
Managers TitleAgeSince
Founder 56 00-07-13
Chief Executive Officer 56 18-07-31
Director of Finance/CFO 48 20-09-27
Members of the board TitleAgeSince
Chairman 63 13-07-17
Director/Board Member 67 12-01-17
Chief Executive Officer 56 18-07-31
More insiders
Date Price Change Volume
24-04-18 1.38 0.00% 5,500
24-04-17 1.38 -49.79% 21,900
24-04-16 2.748 -8.29% 49,300
24-04-15 2.997 -3.17% 5,037
24-04-12 3.095 -3.15% 5,680

Delayed Quote Deutsche Boerse AG, April 19, 2024 at 03:50 pm EDT

More quotes
Pacific Biosciences of California, Inc. is a life science technology company. It is engaged in designing, developing, and manufacturing advanced sequencing solutions that enable scientists and clinical researchers to resolve genetically complex problems. Its products and technology under development stem from two differentiated core technologies, which include its HiFi long-read sequencing technology and its Sequencing by Binding (SBB) short-read sequencing technology. Its products address solutions across a set of applications, including human genetics, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. It has developed HiFi long-read sequencing based on Single-Molecule Real-Time technology, which accurately detects the nucleotide sequence and epigenetic status of individual DNA molecules. Its Revio, Sequel, Sequel II and Sequel IIe instruments conduct, monitor, and analyze single-molecule biochemical reactions in real time.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
1.46 USD
Average target price
5.818 USD
Spread / Average Target
+298.51%
Consensus